Displaying 60 (all) recruiting clinical trials.
-
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)
The purpose of the study is to find out the safety and efficacy of the drug selumetinib in treating patients with low-grade glioma. We want ... -
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
The purpose of the study is to determine the efficacy and safety of how well vitamin D3 given with standard chemotherapy and bevacizumab works in ... -
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
The purpose of the study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia ... -
Phase 3 Randomized Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
The purpose of the trial is to determine the safety and efficacy of the pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus androgen ... -
A Phase 3 Randomized Double-blind Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC (KEYNOTE-992)
The purpose of the study is to determine the safety and efficacy of Pembrolizumab (MK-3475) and Chemoradiotherapy (CRT) for people who have muscle-invasive bladder cancer ... -
A Phase 3 Randomized Open-Label Three Arm Study of PF-06801591 in Combination with BCG (Induction With or Without Maintenance) Versus BCG (Induction and Maintenance) in Participants with HR BCG-Na ve NMIBC (B8011006)
The purpose of the study is to determine the safety and efficacy of PF-06801591 (an anti-PD-1 antibody) combined with Bacillus Calmette- Guerin (BCG) in patients ... -
A Randomized Double-Blind Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
To determine if adding atezolizumab to a paclitaxel, trastuzumab, and pertuzumab improves survival. -
STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab a Phase III Trial (ECOG EA6174)
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that ... -
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The current study is being conducted to evaluate the MRD negativity conversion rate following the addition of daratumumab to lenalidomide, when administered as maintenance treatment ... -
SAR439859 plus palbociclib as first line therapy for patients with ER (+) HER2(-) advanced breast cancer (AMEERA-5)
The purpose of this study is to evaluate whether SAR439859 (a novel hormonal treatment) is a better option compared to Letrozole (a standard hormonal treatment ...